Eli Lilly (Brazil) Today
| LILY34 Stock | BRL 165.13 2.32 1.42% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Eli Lilly is trading at 165.13 as of the 4th of December 2024, a 1.42% up since the beginning of the trading day. The stock's open price was 162.81. Eli Lilly has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Eli Lilly and are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of November 2024 and ending today, the 4th of December 2024. Click here to learn more.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. LILLY DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. The company has 28.51 B outstanding shares. More on Eli Lilly and
Moving together with Eli Stock
Moving against Eli Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Eli Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Eli Lilly's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eli Lilly or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President | David Ricks |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Eli Lilly and (LILY34) is traded on Sao Paulo Exchange in Brazil and employs 47 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 1.82 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eli Lilly's market, we take the total number of its shares issued and multiply it by Eli Lilly's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Eli Lilly operates under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 28.51 B outstanding shares.
Eli Lilly and has accumulated about 3.06 B in cash with 7.26 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68.
Check Eli Lilly Probability Of Bankruptcy
Eli Lilly Risk Profiles
Although Eli Lilly's alpha and beta are two of the key measurements used to evaluate Eli Lilly's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.73 | |||
| Standard Deviation | 2.39 | |||
| Variance | 5.71 | |||
| Risk Adjusted Performance | (0.02) |
Eli Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eli Lilly without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
Eli Lilly Corporate Management
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alonzo Weems | VP Officer | Profile | |
| Jacob Naarden | CEO VP | Profile | |
| Diogo Rau | VP Officer | Profile | |
| Donald Zakrowski | Chief Fin | Profile | |
| Anat Ashkenazi | VP CFO | Profile |
Additional Information and Resources on Investing in Eli Stock
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.